Questions discussed in this category
The patient has no extraocular features of a spondyloarthropathy and is on methotrexate. No active eye disease for past 1 year.
Patient is already on topical high potency corticosteroids.
Any updated safety data on IL-17, IL-23 in pregnancy?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Bissonnette et al., PMID 38324484
How will you counsel patients about the risk and what strategies will you use to mitigate the increased risk of fungal infections seen in the BE COMPL...
In what cases do you discontinue the medication?
Are there ways to overcome barriers in insurance coverage of this combination of treatments?
In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...
205272265922372216552146520789208081720713892161011528914664115521339712908119388683984790107584
Papers discussed in this category
Annals of the rheumatic diseases, 2017-04
Arthritis Care Res (Hoboken), 2018 Aug
Lancet, 2015 Oct 01
Arthritis Care Res (Hoboken),
Journal of psoriasis and psoriatic arthritis, 2019-04
Front Pharmacol, 2019 Mar 26
Annals of the rheumatic diseases, 2009-06
Arthritis Care Res (Hoboken), 2019 Oct
Ann Rheum Dis, 2020 Dec 17
Eur J Dermatol,
Dermatol Ther, 2019 Apr 23
Cutis,
The Journal of rheumatology, 2012-01
JAAD Case Rep, 2019 Oct 10
Current rheumatology reviews, 2019
Am J Clin Dermatol, 2022 Jun 23
Lancet (London, England), 2025 Jan 25
Arthritis research & therapy, 2021 Jan 29
The New England journal of medicine, 2024 Feb 08